<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="30370">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02711345</url>
  </required_header>
  <id_info>
    <org_study_id>CLTT462X2101</org_study_id>
    <secondary_id>2015-003614-24</secondary_id>
    <nct_id>NCT02711345</nct_id>
  </id_info>
  <brief_title>A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers</brief_title>
  <official_title>A Phase I Dose Finding Study of Oral LTT462 in Adult Patients With Advanced Solid Tumors Harboring MAPK Pathway Alterations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase I study of LTT462 in patients with advanced solid tumors that harbor MAPK pathway
      alterations.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 15, 2016</start_date>
  <completion_date type="Anticipated">September 10, 2018</completion_date>
  <primary_completion_date type="Anticipated">September 10, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability as assessed by incidence and severity of adverse events (AEs), dose interruptions, reductions, and dose intensity</measure>
    <time_frame>From Cycle 1 Day 1 until 30 days post study treatment (expected duration approximately 12 months)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and nature of dose limiting toxicities (DLTs) (dose escalation only)</measure>
    <time_frame>1 cycle (28 days).</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>Every 2 cycles after starting LTT462 treatment until end of treatment; expected duration approximately 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>Every 2 cycles after starting LTT462 treatment until end of treatment; expected duration approximately 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Every 2 cycles after starting LTT462 treatment until end of treatment; expected duration approximately 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Every 2 cycles after starting LTT462 treatment until dieseas progression; expected duration approximately 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) - only for dose expansion phase</measure>
    <time_frame>From start of treatment until the date of death; expected duration approximately 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of LTT462</measure>
    <time_frame>Cycle 1 days 1, 2, 3, 8, 15, 16 and 17; Cycle 2 days 1 and 15; Cycle 3 Day 1; Cycle 5 Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Derived PK parameters of LTT462: Area under the curve (AUC)</measure>
    <time_frame>Cycle 1 days 1, 2, 3, 8, 15, 16 and 17; Cycle 2 days 1 and 15; Cycle 3 Day 1; Cycle 5 Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Derived PK parameters of LTT462: Peak Plasma Concentration (Cmax)</measure>
    <time_frame>Cycle 1 days 1, 2, 3, 8, 15, 16 and 17; Cycle 2 days 1 and 15; Cycle 3 Day 1; Cycle 5 Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Derived PK parameters of LTT462: Time to Peak Plasma Concentration (Tmax)</measure>
    <time_frame>Cycle 1 days 1, 2, 3, 8, 15, 16 and 17; Cycle 2 days 1 and 15; Cycle 3 Day 1; Cycle 5 Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Derived PK parameters of LTT462: half-life (T1/2)</measure>
    <time_frame>Cycle 1 days 1, 2, 3, 8, 15, 16 and 17; Cycle 2 days 1 and 15; Cycle 3 Day 1; Cycle 5 Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline of the PD marker DUSP6 in tumor tissue and in blood - dose expansion only</measure>
    <time_frame>Cycle 1 day 1, 2, 3, 15, 16 and 17; upon disease progression (expected duration approximately 12 months)</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">81</enrollment>
  <condition>Ovarian Neoplasms</condition>
  <condition>Non-Small-Cell Lung Carcinoma</condition>
  <condition>Melanoma</condition>
  <condition>Other Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LTT462</intervention_name>
    <description>ERK Inhibitor</description>
    <arm_group_label>Escalation</arm_group_label>
    <arm_group_label>Expansion Group 1</arm_group_label>
    <arm_group_label>Expansion Group 2</arm_group_label>
    <arm_group_label>Expansion Group 3</arm_group_label>
    <arm_group_label>Expansion Group 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient (male or female) ≥18 years of age

          -  ECOG (Eastern Cooperative Oncology Group) performance status ≤1

          -  Must have progressed following standard therapy, or for whom, in the opinion of the
             Investigator, no effective standard therapy exists, is tolerated or appropriate.

          -  Patients must be willing and able to undergo study required biopsies.

          -  Presence of at least one measurable lesion according to RECIST v1.1.

          -  Documented MAPK pathway alteration

        Exclusion Criteria:

          -  Prior treatment with ERK inhibitors.

          -  History or current evidence of retinal vein occlusion (RVO) or current risk factors
             for RVO.

          -  Any medical condition that would, in the investigator's judgment, prevent the
             patient's participation in the clinical study due to safety concerns or compliance
             with clinical study procedures.

          -  Patients receiving proton pump inhibitors (PPI) which cannot be discontinued 3 days
             prior to the start study treatment and for the duration of the study.

          -  Patients with malignant disease other than that being treated in the study.

          -  Clinically significant cardiac disease.

        Other protocol-defined exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center SC - LXH254X2101</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hannah Beer</last_name>
      <email>beerh@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Gopakumar Iyer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center/University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cymone A. McNeil</last_name>
      <phone>713-792-2828</phone>
      <email>cvmcneil@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Filip Janku</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bellinzona</city>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Japan</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>France</country>
    <country>Italy</country>
    <country>Netherlands</country>
  </removed_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 24, 2017</lastchanged_date>
  <firstreceived_date>February 16, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LTT462</keyword>
  <keyword>ERK</keyword>
  <keyword>MAPK</keyword>
  <keyword>solid tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
